Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study to arrest progression of cognitive decline in insulin-treated type 2 diabetes
2017-004454-42Phase 4Active
- Sponsor
- Vall d'Hebron Research Institute
- Start
- Jan 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of insulin glargine in type 2 diabetes mellitus (T2DM), Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI) (2 arms), sponsored by Vall d'Hebron Research Institute. Primary endpoint: Alzheimer's disease diagnosis. Started Jan 2018; status: active.
02
Drugs
insulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on 2017-004454-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004454-42.